Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed chronic lymphocytic leukemia (CLL) by NCI-WG immunophenotype and blood criteria~  * Documentation of current or prior peripheral blood (PB) or bone marrow (BM) immunophenotype compatible with CLL~    * Patients who currently do not have \> 5,000/mm³ absolute lymphocytosis are eligible if they have previously met PB lymphocytosis criteria and have a current immunophenotype documenting monoclonal B lymphocytosis morphologically and immunophenotypically compatible with CLL~* Intermediate-risk (Rai stage I or II) or high-risk (Rai stage III or IV) disease, including any of the following:~  * Rai stage I disease with lymphocytosis and enlarged nodes~ * Rai stage II disease with lymphocytosis plus splenomegaly and/or hepatomegaly (nodes positive or negative)~ * Rai stage III disease with lymphocytosis plus anemia~ * Rai stage IV disease with lymphocytosis and thrombocytopenia~* Must require treatment with active disease, experiencing disease related symptoms, or having deterioration of blood counts, meeting ≥ 1 of the following criteria:~  * Presence of ≥ 1 of the following disease-related symptoms:~    * Weight loss \> 10% within the past 6 months~   * Extreme fatigue (i.e., ECOG performance status 2: cannot work or unable to perform usual activities)~   * Fever \> 100.5°F for 2 weeks without evidence of infection~   * Night sweats without evidence of infection~ * Evidence of progressive marrow failure, as manifested by worsening of anemia (hemoglobin \< 10 g/dL), thrombocytopenia (platelet count \< 100,000/mm³), and/or neutropenia (neutrophil count \< 2,000/mm³)~ * Massive (i.e., \> 6 cm below left costal margin) or progressive splenomegaly or discomfort from splenomegaly~ * Massive nodes or clusters (i.e., \> 10 cm in longest diameter), progressive adenopathy, or discomfort from lymphadenopathy~ * Deterioration of blood counts and/or progressive lymphocytosis, with an increase of ≥ 10% documented over a 2-month period OR an anticipated doubling time \< 6 months~* Relapsed disease~  * Must receive at least 1, but no more than 3, prior chemotherapy regimens with any cytotoxic agent or antibody therapy~    * No fludarabine refractory disease~      * Responded to prior fludarabine without relapse or disease progression for at least 6 months~* Patients with a history of Coombs-positive hemolytic anemia are eligible provided recovery from treatment of hemolysis and off steroids~* No stage 0 CLL~* No known CNS involvement~* Life expectancy \> 6 months~* ECOG performance status 0-2 OR Karnofsky performance status 70-100%~* Absolute neutrophil count ≥ 1,000/mm³~* Platelets ≥ 30,000/mm³~* Bilirubin ≤ 2 mg/dL~* AST/ALT ≤ 2.5 times upper limit of normal (ULN)~* Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min (for patients with creatinine levels above normal)~* No currently active second malignancy~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patient must use effective contraception prior to and during study participation~* No uncontrolled hypertension, defined as blood pressure (BP) \> 150/100 mm Hg on 2 different measurements at least 1 day apart with either systolic or diastolic number meeting this definition~  * Patients may later enter the study, if they have achieved stable BP (i.e., \< 140/90 mm Hg) on a regimen of ≤ 2 drugs after 6-8 weeks of therapy~* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib~* No uncontrolled intercurrent illness including, but not limited to, any of the following:~  * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Psychiatric illness or social situations that would limit compliance with the study requirements~* No active infection requiring systemic antibiotics~* No evidence of bleeding diathesis~* No evidence of bowel perforation or obstruction risk~* No swallowing dysfunction leading to difficulty taking the study drug~* See Disease Characteristics~* Recovered from prior therapy~* At least 2 weeks since prior antibiotic therapy~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy~* At least 12 weeks since prior monoclonal antibody~* Concurrent warfarin for anticoagulation allowed provided all of the following are met:~  * On a stable therapeutic dose~ * INR ≤ 3~ * No active bleeding or pathological condition that carries high-risk of bleeding~* No prior MAPK signaling inhibitor agents or anti-angiogenesis agents~* No concurrent combination anti-retroviral therapy for HIV-positive patients~* No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine, or phenobarbital), rifampin, or Hypericum perforatum (St. John's wort)~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (sorafenib tosylate) (Type: EXPERIMENTAL): Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).